Sugi Predict

Sugi Predict / Compounds / SCHEMBL3782237

SCHEMBL3782237

SCHEMBL3782237

Cc1cn2c(CC(=O)O)csc2n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 1/20 0.48
▸ MAPK10 P53779 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ ALOX15 P16050 1/20 0.40
▸ TP53 P04637 2/20 0.38
▸ GABRA5 P31644 1/20 0.37
▸ GABRB2 P47870 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CYP19A1 P11511 1/20 0.36
▸ EGLN1 Q9GZT9 1/20 0.36
▸ ADAMTS5 Q9UNA0 1/20 0.36
▸ THRB P10828 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ AKT2 P31751 1/20 0.35
▸ AKT3 Q9Y243 1/20 0.35
▸ MAPK8 P45983 1/20 0.35
▸ MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21196913 0.86 MAPK9 (0.47) MAPK9MAPK10SMN1; SMN2ALOX15TP53
SCHEMBL8556217 0.80 MAPK9 (0.41) MAPK9MAPK10SMN1; SMN2ALOX15TP53
SCHEMBL14046222 0.80 MAPK9 (0.41) MAPK9MAPK10SMN1; SMN2ALOX15TP53
SCHEMBL8809096 0.75 MAPK9 (0.39) MAPK9MAPK10SMN1; SMN2ALOX15TP53
SCHEMBL2998557 0.75 ALOX15 (0.40) MAPK9MAPK10SMN1; SMN2ALOX15HSD17B10
SCHEMBL27151036 0.73 SMN1; SMN2 (0.41) MAPK9MAPK10SMN1; SMN2GABRA5GABRB2
SCHEMBL3460400 0.71 ALOX15 (0.53) SMN1; SMN2ALOX15TP53HSD17B10MAPT
SCHEMBL27138363 0.71 ALOX15 (0.66) SMN1; SMN2ALOX15TP53HSD17B10MAPT
SCHEMBL27364077 0.69 ALOX15 (0.34) MAPK9MAPK10SMN1; SMN2ALOX15TP53
SCHEMBL6037690 0.66 PLA2G4A (0.38) SMN1; SMN2ALOX15THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220081427-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2022-03-17 — — US disclosed
US-20200277285-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2020-09-03 — — US disclosed
US-20200039972-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2020-02-06 — — US disclosed
US-20190194176-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2019-06-27 — — US disclosed
US-20180319780-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2018-11-08 — — US disclosed
US-20180037577-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2018-02-08 — — US disclosed
EP-2393806-B1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARM INC (US) 2017-10-25 — — EP disclosed
US-9796706-B2 Inhibitors of Jun N-terminal kinase IMAGO PHARMACEUTICALS, INC. (US) 2017-10-24 — — US disclosed
US-20170107209-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2017-04-20 — — US disclosed
US-20150259330-A1 INHIBITORS OF JUN N-TERMINAL KINASE IMAGO PHARMACEUTICALS, INC. (US) 2015-09-17 — — US disclosed
US-9073891-B2 Inhibitors of Jun N-terminal kinase IMAGO PHARMACEUTICALS, INC. (US) 2015-07-07 — — US disclosed
US-8450363-B2 Inhibitors of Jun N-terminal kinase ELAN PHARMACEUTICALS, INC. (US) 2013-05-28 — — US disclosed
US-20130072494-A1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARMACEUTICALS, INC. 2013-03-21 — — US disclosed
EP-2393806-A1 INHIBITORS OF JUN N-TERMINAL KINASE Elan Pharmaceuticals Inc. (US) 2011-12-14 — — EP disclosed
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase ELAN PHARMACETICALS, INC. 2010-12-30 — — US disclosed
WO-2010091310-A1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039972-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20190194176-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20150259330-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20170107209-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20180037577-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20130072494-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20220081427-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20200277285-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20180319780-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase CHUK, MAPK6, MAPK3 MAPK9 16/4885MAPK10 21/4885SMN1; SMN2 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.